Compare PFSA & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PFSA | TNON |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 9.8M |
| IPO Year | N/A | 2022 |
| Metric | PFSA | TNON |
|---|---|---|
| Price | $2.97 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 241.9K | ★ 2.4M |
| Earning Date | 04-02-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,233,000.00 |
| Revenue This Year | N/A | $19.56 |
| Revenue Next Year | N/A | $71.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 122.22 | N/A |
| 52 Week Low | $2.90 | $0.64 |
| 52 Week High | $957.00 | $5.85 |
| Indicator | PFSA | TNON |
|---|---|---|
| Relative Strength Index (RSI) | 92.02 | 34.54 |
| Support Level | $0.05 | $0.68 |
| Resistance Level | $4.22 | $0.89 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 70.34 | 20.40 |
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.